CMV specific cytokine release assay in whole blood is optimized by combining synthetic CMV peptides and toll like receptor agonists

2014/10/30 by Werner Dammermann, David Bochmann, Frank Bentzien +5 · 7 citations
Medicine · #Cytomegalovirus and herpesvirus research #Systemic Lupus Erythematosus Research #Viral Infections and Immunology Research

paper · doi:10.1016/j.jim.2014.10.011

Cited by

• Complement factors C3a and C5a mimick a proinflammatory microenvironment and increase HBV IGRA sensitivity. [europepmc]
• CMV-Specific Immune Response-New Patients, New Insight: Central Role of Specific IgG during Infancy and Long-Lasting Immune Deficiency after Allogenic Stem Cell Transplantation. [europepmc]
• Toll-Like Receptor-Induced Immune Responses During Early Childhood and Their Associations With Clinical Outcomes Following Acute Illness Among Infants in Sub-Saharan Africa. [europepmc]
• Effect of Immune-Modulatory Interventions on Asymptomatic Cytomegalovirus Shedding During Suppressive Antiretroviral Therapy. [europepmc]
• Evaluation of three novel antigens and costimulatory agents for improvement of M. Tuberculosis specific interferon gamma release assays. [europepmc]
• Pneumocystis Jirovecii Pneumonia: The Potential of KEX1, MSG1, and MSG2 as Key Antigens in Cytokine Release Assays. [europepmc]
• A safe, T cell-inducing heterologous vaccine against elephant endotheliotropic herpesvirus in a proof-of-concept study. [europepmc]